Oliver Plettenburg
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Oliver Plettenburg has a total of 233 co-authors. Here are the top co-authors by number of shared publications:
- Michael Sattler
Institute of Structural Biology, Molecular Targets and Therapeutics Center, Helmholtz Munich, Neuherberg, Germany
5 shared publications Dominik Lenhart
Institute of Structural Biology, Helmholtz Zentrum München, Ingolstädter Landstrasse 1, 85764 Neuherberg, Germany
3 shared publicationsChristin Ahlbrecht
German Center for Diabetes Research (DZD), Neuherberg, Germany
2 shared publications- Daniel Krappmann
Research Unit Signaling and Translation, Molecular Targets and Therapeutics Center, Helmholtz Zentrum München-German Research Center for Environmental Health, Neuherberg, Germany
2 shared publications Grzegorz M. Popowicz
Institute of Structural Biology, Helmholtz Zentrum München, Ingolstädter Landstrasse 1, 85764 Neuherberg, Germany
2 shared publicationsIsabel Hamp
Institute for Medicinal Chemistry, Helmholtz Zentrum München–German Research Center for Environmental Health, 30167 Hannover, Germany
2 shared publications
Latest Publications
- Open Access
Nano‐Optical Biomolecular Interaction Sensing Within Complex Media via Peptide Hybrid Ligand Conjugation
Protein–protein interactions (PPIs) govern most biological processes and are frequently altered in disease. However, in vitro characterization methods are often limited to binding affinities, specialized instrumentation, or are susceptible to extended‐surface artifacts. Moreover, many remain incompatible with physiological media. Nano‐optical biosensing based on nanoparticle (NP) localized surface plasmon resonances (LSPRs) offers an attractive in‐solution alternative, but their performance has been limited in complex environments. Here, we present a solution‐phase optical platform based on plasmonic nanoparticles functionalized with programmable peptide‐hybrid ligands. We use sequence‐defined ligands that combine nanoparticle anchoring, suppression of non‐specific interactions, and site‐specific bioconjugation. Unlike conventional polymers, these ligands are molecularly precise via solid‐phase peptide synthesis. We show how this architecture effectively suppresses nonspecific adsorption while preserving colloidal stability and optical performance, and can be adapted to diverse protein targets through click chemistry and Sortase‐mediated ligation. This platform enables high‐sensitivity, label‐free PPI detection via standard UV–vis spectrophotometry and minimal sample amounts. We quantify binding affinities of low molecular‐weight proteins directly in undiluted serum, along with kinetic profiling in buffer. Furthermore, we demonstrate applicability over multiple protein pairs in buffer and serum, as well as proof‐of‐concept detection and quantification in human serum, highlighting its potential for future diagnostic applications.
Open AccessNano‐Optical Biomolecular Interaction Sensing Within Complex Media via Peptide Hybrid Ligand Conjugation
Protein–protein interactions (PPIs) govern most biological processes and are frequently altered in disease. However, in vitro characterization methods are often limited to binding affinities, specialized instrumentation, or are susceptible to extended‐surface artifacts. Moreover, many remain incompatible with physiological media. Nano‐optical biosensing based on nanoparticle (NP) localized surface plasmon resonances (LSPRs) offers an attractive in‐solution alternative, but their performance has been limited in complex environments. Here, we present a solution‐phase optical platform based on plasmonic nanoparticles functionalized with programmable peptide‐hybrid ligands. We use sequence‐defined ligands that combine nanoparticle anchoring, suppression of non‐specific interactions, and site‐specific bioconjugation. Unlike conventional polymers, these ligands are molecularly precise via solid‐phase peptide synthesis. We show how this architecture effectively suppresses nonspecific adsorption while preserving colloidal stability and optical performance, and can be adapted to diverse protein targets through click chemistry and Sortase‐mediated ligation. This platform enables high‐sensitivity, label‐free PPI detection via standard UV–vis spectrophotometry and minimal sample amounts. We quantify binding affinities of low molecular‐weight proteins directly in undiluted serum, along with kinetic profiling in buffer. Furthermore, we demonstrate applicability over multiple protein pairs in buffer and serum, as well as proof‐of‐concept detection and quantification in human serum, highlighting its potential for future diagnostic applications.
- Open Access
- 28 October 2026
- Published by Wiley in Advanced Functional Materials
- p. e79191
Selenium‐Integrated Cyanine Dye With Enhanced Photophysical Properties for Optoacoustic‐Guided Cancer Imaging and Therapy
Near‐infrared (NIR) cyanine dyes demonstrate considerable promise in medical applications, notably in cancer diagnosis, due to their favourable fluorescence properties and biocompatibility. However, these dyes generally have low photostability and tend to aggregate in aqueous solution, which can constrain their usefulness for prolonged in vivo imaging and phototherapy applications. Here, we report the synthesis of a selenium‐integrated NIR cyanine dye, Se‐Cyn, designed to modulate its electronic and photophysical properties. Se‐Cyn demonstrates high photostability, molar absorptivity, photothermal conversion efficiency (PCE), and sustained optoacoustic (OptA) contrast under prolonged irradiation. Se‐Cyn nanoparticles (NPs) outperform the indocyanine green (ICG) NPs, exhibiting PCE of 59% and a 1.36‐fold higher OptA generation efficiency. Additionally, nano‐formulated Se‐Cyn NPs show excellent aqueous stability and improved bioavailability, supporting its suitability for biological applications. Furthermore, Se‐Cyn NPs accumulate in tumors following systemic administration, enabling effective OptA tumor imaging. Together with their strong photodynamic and photothermal properties, these NPs show considerable potential for cancer theranostics.
- 28 October 2026
- Published by Wiley in Advanced Functional Materials
- p. e79191
Open AccessSelenium‐Integrated Cyanine Dye With Enhanced Photophysical Properties for Optoacoustic‐Guided Cancer Imaging and Therapy
Near‐infrared (NIR) cyanine dyes demonstrate considerable promise in medical applications, notably in cancer diagnosis, due to their favourable fluorescence properties and biocompatibility. However, these dyes generally have low photostability and tend to aggregate in aqueous solution, which can constrain their usefulness for prolonged in vivo imaging and phototherapy applications. Here, we report the synthesis of a selenium‐integrated NIR cyanine dye, Se‐Cyn, designed to modulate its electronic and photophysical properties. Se‐Cyn demonstrates high photostability, molar absorptivity, photothermal conversion efficiency (PCE), and sustained optoacoustic (OptA) contrast under prolonged irradiation. Se‐Cyn nanoparticles (NPs) outperform the indocyanine green (ICG) NPs, exhibiting PCE of 59% and a 1.36‐fold higher OptA generation efficiency. Additionally, nano‐formulated Se‐Cyn NPs show excellent aqueous stability and improved bioavailability, supporting its suitability for biological applications. Furthermore, Se‐Cyn NPs accumulate in tumors following systemic administration, enabling effective OptA tumor imaging. Together with their strong photodynamic and photothermal properties, these NPs show considerable potential for cancer theranostics.
- Open Access
It’s Not Always Crystal Clear: In-Pocket Analysis for Understanding Binding Site Microenvironment Properties
Structural biology enabled key advances in biochemistry, drug discovery, and AI-driven three-dimensional structure modelling. Despite its importance, reliable and general computational tools for chemical validation of structural models remain limited, especially when small-molecule ligands are involved. This challenge is exacerbated when experimental resolution is insufficient to define interaction chemistry, leaving critical interpretations ambiguous. We introduce In-Pocket, a quantum mechanical optimisation method biased by experimental data that evaluates the chemical nature of protein-ligand binding interfaces. In-Pocket improves model quality, corrects chemically inconsistent structures, and identifies the energetically most favourable ligand-conformers within biomacromolecular complexes. The approach is generally applicable to a wide range of systems, including those containing transition metals. Benchmarking demonstrates that In-Pocket enhances the reliability of legacy and newly solved structures. With automated, user-friendly routine chemical validation, In-Pocket offers unique opportunities to improve the integrity of structural databases and impact diverse domains: from molecular biology to rational drug design and application of generative AI.
Open AccessIt’s Not Always Crystal Clear: In-Pocket Analysis for Understanding Binding Site Microenvironment Properties
Structural biology enabled key advances in biochemistry, drug discovery, and AI-driven three-dimensional structure modelling. Despite its importance, reliable and general computational tools for chemical validation of structural models remain limited, especially when small-molecule ligands are involved. This challenge is exacerbated when experimental resolution is insufficient to define interaction chemistry, leaving critical interpretations ambiguous. We introduce In-Pocket, a quantum mechanical optimisation method biased by experimental data that evaluates the chemical nature of protein-ligand binding interfaces. In-Pocket improves model quality, corrects chemically inconsistent structures, and identifies the energetically most favourable ligand-conformers within biomacromolecular complexes. The approach is generally applicable to a wide range of systems, including those containing transition metals. Benchmarking demonstrates that In-Pocket enhances the reliability of legacy and newly solved structures. With automated, user-friendly routine chemical validation, In-Pocket offers unique opportunities to improve the integrity of structural databases and impact diverse domains: from molecular biology to rational drug design and application of generative AI.
- Open Access
- 25 November 2024
- Published by Springer Nature in Nature Metabolism
- Vol. 6 (12) , 2374-2390
Inceptor binds to and directs insulin towards lysosomal degradation in β cells
Blunted first-phase insulin secretion and insulin deficiency are indicators of β cell dysfunction and diabetes manifestation. Therefore, insights into molecular mechanisms that regulate insulin homeostasis might provide entry sites to replenish insulin content and restore β cell function. Here, we identify the insulin inhibitory receptor (inceptor; encoded by the gene IIR/ELAPOR1) as an insulin-binding receptor that regulates insulin stores by lysosomal degradation. Using human induced pluripotent stem cell (SC)-derived islets, we show that IIR knockout (KO) results in enhanced SC β cell differentiation and survival. Strikingly, extended in vitro culture of IIR KO SC β cells leads to greatly increased insulin content and glucose-stimulated insulin secretion (GSIS). We find that inceptor localizes to clathrin-coated vesicles close to the plasma membrane and in the trans-Golgi network as well as in secretory granules, where it acts as a sorting receptor to direct proinsulin and insulin towards lysosomal degradation. Targeting inceptor using a monoclonal antibody increases proinsulin and insulin content and improves SC β cell GSIS. Altogether, our findings reveal the basic mechanisms of β cell insulin turnover and identify inceptor as an insulin degradation receptor.
- 25 November 2024
- Published by Springer Nature in Nature Metabolism
- Vol. 6 (12) , 2374-2390
Open AccessInceptor binds to and directs insulin towards lysosomal degradation in β cells
Blunted first-phase insulin secretion and insulin deficiency are indicators of β cell dysfunction and diabetes manifestation. Therefore, insights into molecular mechanisms that regulate insulin homeostasis might provide entry sites to replenish insulin content and restore β cell function. Here, we identify the insulin inhibitory receptor (inceptor; encoded by the gene IIR/ELAPOR1) as an insulin-binding receptor that regulates insulin stores by lysosomal degradation. Using human induced pluripotent stem cell (SC)-derived islets, we show that IIR knockout (KO) results in enhanced SC β cell differentiation and survival. Strikingly, extended in vitro culture of IIR KO SC β cells leads to greatly increased insulin content and glucose-stimulated insulin secretion (GSIS). We find that inceptor localizes to clathrin-coated vesicles close to the plasma membrane and in the trans-Golgi network as well as in secretory granules, where it acts as a sorting receptor to direct proinsulin and insulin towards lysosomal degradation. Targeting inceptor using a monoclonal antibody increases proinsulin and insulin content and improves SC β cell GSIS. Altogether, our findings reveal the basic mechanisms of β cell insulin turnover and identify inceptor as an insulin degradation receptor.
- 5 August 2024
- Published by Royal Society of Chemistry (RSC) in Lab on a Chip
- Vol. 24 (17) , 4172-4181
Patterned thin film enzyme electrodes via spincoating and glutaraldehyde vapor crosslinking: towards scalable fabrication of integrated sensor-on-CMOS devices
Effective continuous glucose monitoring solutions require consistent sensor performance over the lifetime of the device, a manageable variance between devices, and the capability of high volume, low cost production. Here we present a novel and microfabrication-compatible method of depositing and stabilizing enzyme layers on top of planar electrodes that can aid in the mass production of sensors while also improving their consistency. This work is focused on the fragile biorecognition layer as that has been a critical difficulty in the development of microfabricated sensors. We test this approach with glucose oxidase (GOx) and evaluate the sensor performance with amperometric measurements of in vitro glucose concentrations. Spincoating was used to deposit a uniform enzyme layer across a wafer, which was subsequently immobilized via glutaraldehyde vapor crosslinking and patterned via liftoff. This yielded an approximately 300 nm thick sensing layer which was applied to arrays of microfabricated platinum electrodes built on blank wafers. Taking advantage of their planar array format, measurements were then performed in high-throughput parallel instrumentation. Due to their thin structure, the coated electrodes exhibited subsecond stabilization times after the bias potential was applied. The deposited enzyme layers were measured to provide a sensitivity of 2.3 ± 0.2 μA mM−1 mm−2 with suitable saturation behavior and minimal performance shift observed over extended use. The same methodology was then demonstrated directly on top of wireless CMOS potentiostats to build a monolithic sensor with similar measured performance. This work demonstrates the effectiveness of the combination of spincoating and vapor stabilization processes for wafer scale enzymatic sensor functionalization and the potential for scalable fabrication of monolithic sensor-on-CMOS devices.
- 5 August 2024
- Published by Royal Society of Chemistry (RSC) in Lab on a Chip
- Vol. 24 (17) , 4172-4181
Patterned thin film enzyme electrodes via spincoating and glutaraldehyde vapor crosslinking: towards scalable fabrication of integrated sensor-on-CMOS devices
Effective continuous glucose monitoring solutions require consistent sensor performance over the lifetime of the device, a manageable variance between devices, and the capability of high volume, low cost production. Here we present a novel and microfabrication-compatible method of depositing and stabilizing enzyme layers on top of planar electrodes that can aid in the mass production of sensors while also improving their consistency. This work is focused on the fragile biorecognition layer as that has been a critical difficulty in the development of microfabricated sensors. We test this approach with glucose oxidase (GOx) and evaluate the sensor performance with amperometric measurements of in vitro glucose concentrations. Spincoating was used to deposit a uniform enzyme layer across a wafer, which was subsequently immobilized via glutaraldehyde vapor crosslinking and patterned via liftoff. This yielded an approximately 300 nm thick sensing layer which was applied to arrays of microfabricated platinum electrodes built on blank wafers. Taking advantage of their planar array format, measurements were then performed in high-throughput parallel instrumentation. Due to their thin structure, the coated electrodes exhibited subsecond stabilization times after the bias potential was applied. The deposited enzyme layers were measured to provide a sensitivity of 2.3 ± 0.2 μA mM−1 mm−2 with suitable saturation behavior and minimal performance shift observed over extended use. The same methodology was then demonstrated directly on top of wireless CMOS potentiostats to build a monolithic sensor with similar measured performance. This work demonstrates the effectiveness of the combination of spincoating and vapor stabilization processes for wafer scale enzymatic sensor functionalization and the potential for scalable fabrication of monolithic sensor-on-CMOS devices.
- Open Access
- 5 January 2023
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 145 (2) , 851-863
The Myxobacterial Antibiotic Myxovalargin: Biosynthesis, Structural Revision, Total Synthesis, and Molecular Characterization of Ribosomal Inhibition
Resistance of bacterial pathogens against antibiotics is declared by WHO as a major global health threat. As novel antibacterial agents are urgently needed, we re-assessed the broad-spectrum myxobacterial antibiotic myxovalargin and found it to be extremely potent against Mycobacterium tuberculosis. To ensure compound supply for further development, we studied myxovalargin biosynthesis in detail enabling production via fermentation of a native producer. Feeding experiments as well as functional genomics analysis suggested a structural revision, which was eventually corroborated by the development of a concise total synthesis. The ribosome was identified as the molecular target based on resistant mutant sequencing, and a cryo-EM structure revealed that myxovalargin binds within and completely occludes the exit tunnel, consistent with a mode of action to arrest translation during a late stage of translation initiation. These studies open avenues for structure-based scaffold improvement toward development as an antibacterial agent.
- 5 January 2023
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 145 (2) , 851-863
Open AccessThe Myxobacterial Antibiotic Myxovalargin: Biosynthesis, Structural Revision, Total Synthesis, and Molecular Characterization of Ribosomal Inhibition
Resistance of bacterial pathogens against antibiotics is declared by WHO as a major global health threat. As novel antibacterial agents are urgently needed, we re-assessed the broad-spectrum myxobacterial antibiotic myxovalargin and found it to be extremely potent against Mycobacterium tuberculosis. To ensure compound supply for further development, we studied myxovalargin biosynthesis in detail enabling production via fermentation of a native producer. Feeding experiments as well as functional genomics analysis suggested a structural revision, which was eventually corroborated by the development of a concise total synthesis. The ribosome was identified as the molecular target based on resistant mutant sequencing, and a cryo-EM structure revealed that myxovalargin binds within and completely occludes the exit tunnel, consistent with a mode of action to arrest translation during a late stage of translation initiation. These studies open avenues for structure-based scaffold improvement toward development as an antibacterial agent.
- Open Access
- 24 December 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 7 (52) , eabb3673
Phenotypic drug screening in a human fibrosis model identified a novel class of antifibrotic therapeutics
Innovative high-content screening platform identified N -(2-butoxyphenyl)-3-(phenyl)acrylamides as novel antifibrotics.
- 24 December 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 7 (52) , eabb3673
Open AccessPhenotypic drug screening in a human fibrosis model identified a novel class of antifibrotic therapeutics
Innovative high-content screening platform identified N -(2-butoxyphenyl)-3-(phenyl)acrylamides as novel antifibrotics.
- 26 November 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 6 (65) , eabh2095
TRAF6 prevents fatal inflammation by homeostatic suppression of MALT1 protease
TRAF6 maintains immune homeostasis by preventing deregulated activation of the MALT1 paracaspase in T cells.
- 26 November 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 6 (65) , eabh2095
TRAF6 prevents fatal inflammation by homeostatic suppression of MALT1 protease
TRAF6 maintains immune homeostasis by preventing deregulated activation of the MALT1 paracaspase in T cells.
- Open Access
- 1 October 2021
- Published by American Chemical Society (ACS) in Journal of Chemical Information and Modeling
- Vol. 61 (10) , 5256-5268
Computer-Aided Design and Synthesis of a New Class of PEX14 Inhibitors: Substituted 2,3,4,5-Tetrahydrobenzo[F][1,4]oxazepines as Potential New Trypanocidal Agents
African and American trypanosomiases are estimated to affect several million people across the world, with effective treatments distinctly lacking. New, ideally oral, treatments with higher efficacy against these diseases are desperately needed. Peroxisomal import matrix (PEX) proteins represent a very interesting target for structure- and ligand-based drug design. The PEX5–PEX14 protein–protein interface in particular has been highlighted as a target, with inhibitors shown to disrupt essential cell processes in trypanosomes, leading to cell death. In this work, we present a drug development campaign that utilizes the synergy between structural biology, computer-aided drug design, and medicinal chemistry in the quest to discover and develop new potential compounds to treat trypanosomiasis by targeting the PEX14–PEX5 interaction. Using the structure of the known lead compounds discovered by Dawidowski et al. as the template for a chemically advanced template search (CATS) algorithm, we performed scaffold-hopping to obtain a new class of compounds with trypanocidal activity, based on 2,3,4,5-tetrahydrobenzo[f][1,4]oxazepines chemistry. The initial compounds obtained were taken forward to a first round of hit-to-lead optimization by synthesis of derivatives, which show activities in the range of low- to high-digit micromolar IC50 in the in vitro tests. The NMR measurements confirm binding to PEX14 in solution, while immunofluorescent microscopy indicates disruption of protein import into the glycosomes, indicating that the PEX14–PEX5 protein–protein interface was successfully disrupted. These studies result in development of a novel scaffold for future lead optimization, while ADME testing gives an indication of further areas of improvement in the path from lead molecules toward a new drug active against trypanosomes.
- 1 October 2021
- Published by American Chemical Society (ACS) in Journal of Chemical Information and Modeling
- Vol. 61 (10) , 5256-5268
Open AccessComputer-Aided Design and Synthesis of a New Class of PEX14 Inhibitors: Substituted 2,3,4,5-Tetrahydrobenzo[F][1,4]oxazepines as Potential New Trypanocidal Agents
African and American trypanosomiases are estimated to affect several million people across the world, with effective treatments distinctly lacking. New, ideally oral, treatments with higher efficacy against these diseases are desperately needed. Peroxisomal import matrix (PEX) proteins represent a very interesting target for structure- and ligand-based drug design. The PEX5–PEX14 protein–protein interface in particular has been highlighted as a target, with inhibitors shown to disrupt essential cell processes in trypanosomes, leading to cell death. In this work, we present a drug development campaign that utilizes the synergy between structural biology, computer-aided drug design, and medicinal chemistry in the quest to discover and develop new potential compounds to treat trypanosomiasis by targeting the PEX14–PEX5 interaction. Using the structure of the known lead compounds discovered by Dawidowski et al. as the template for a chemically advanced template search (CATS) algorithm, we performed scaffold-hopping to obtain a new class of compounds with trypanocidal activity, based on 2,3,4,5-tetrahydrobenzo[f][1,4]oxazepines chemistry. The initial compounds obtained were taken forward to a first round of hit-to-lead optimization by synthesis of derivatives, which show activities in the range of low- to high-digit micromolar IC50 in the in vitro tests. The NMR measurements confirm binding to PEX14 in solution, while immunofluorescent microscopy indicates disruption of protein import into the glycosomes, indicating that the PEX14–PEX5 protein–protein interface was successfully disrupted. These studies result in development of a novel scaffold for future lead optimization, while ADME testing gives an indication of further areas of improvement in the path from lead molecules toward a new drug active against trypanosomes.
- 15 July 2021
- Published by Taylor & Francis in Expert Opinion on Therapeutic Patents
- Vol. 31 (12) , 1079-1096
A patent review of MALT1 inhibitors (2013-present)
MALT1 is the only human paracaspase, a protease with unique cleavage activity and substrate specificity. As a key regulator of immune responses, MALT1 has attracted attention as an immune modulator...
- 15 July 2021
- Published by Taylor & Francis in Expert Opinion on Therapeutic Patents
- Vol. 31 (12) , 1079-1096
A patent review of MALT1 inhibitors (2013-present)
MALT1 is the only human paracaspase, a protease with unique cleavage activity and substrate specificity. As a key regulator of immune responses, MALT1 has attracted attention as an immune modulator...